What are the advantages and disadvantages of atorvastatin and rosuvastatin, including a detailed head‑to‑head comparison?

Head-to-Head Comparison: Atorvastatin vs Rosuvastatin

Both atorvastatin and rosuvastatin are highly effective high-intensity statins with comparable cardiovascular outcomes, but rosuvastatin demonstrates superior LDL-C lowering potency at equivalent doses while atorvastatin may offer advantages in specific populations including those with elevated liver enzymes or heart failure.

LDL-C Lowering Efficacy

Rosuvastatin is more potent at equivalent doses:

• Rosuvastatin 10 mg reduces LDL-C by approximately 52%, compared to atorvastatin 10 mg at 43% reduction 1, 2
• At 1:1 dose ratios, rosuvastatin achieves 8.2% greater LDL-C reduction than atorvastatin across all doses 3
• Rosuvastatin 20 mg produces similar LDL-C lowering to atorvastatin 40-80 mg 2, 3
• Meta-analysis confirms rosuvastatin reduces LDL-C by 55.66 mg/dL versus atorvastatin's 51.49 mg/dL 4

Both drugs qualify as high-intensity statins at appropriate doses:

• Atorvastatin 40-80 mg achieves ≥50% LDL-C reduction 1
• Rosuvastatin 20-40 mg achieves ≥50% LDL-C reduction 1

Effects on Other Lipid Parameters

Rosuvastatin demonstrates superior HDL-C elevation:

• Rosuvastatin increases HDL-C by 7.7-9.6% compared to atorvastatin's 2.1-6.8% 3
• Meta-analysis shows rosuvastatin raises HDL-C by 3.87 mg/dL versus atorvastatin's 1.85 mg/dL 4

Rosuvastatin provides greater triglyceride reduction:

• Rosuvastatin reduces triglycerides by 31.98 mg/dL compared to atorvastatin's 24.76 mg/dL 4
• This difference is statistically significant across dose ranges 3

Cardiovascular Outcomes

Clinical outcomes are largely comparable between the two statins:

• The LODESTAR trial (4,400 patients with coronary artery disease) found no significant difference in the composite outcome of death, MI, stroke, or revascularization at 3 years (8.7% rosuvastatin vs 8.2% atorvastatin, HR 1.06, p=0.58) 5
• Real-world data from 285,680 patients showed small differences favoring rosuvastatin: 6-year mortality difference of -1.03% in one database and -1.38% in another, though these differences were modest 6
• Both statins demonstrated ASCVD risk reduction in primary prevention trials 7

Safety Profile Differences

Diabetes Risk

Rosuvastatin carries higher risk of new-onset diabetes:

• LODESTAR trial showed 7.2% incidence with rosuvastatin versus 5.3% with atorvastatin (HR 1.39, p=0.03) 5
• This represents a 39% increased relative risk requiring initiation of antidiabetic medications 5

Cataract Risk

Rosuvastatin associated with increased cataract surgery:

• 2.5% incidence with rosuvastatin versus 1.5% with atorvastatin (HR 1.66, p=0.02) 5

Hepatotoxicity

Atorvastatin may pose greater risk in patients with elevated liver enzymes:

• In AMI patients with elevated liver enzymes, atorvastatin was associated with 29% higher 1-year mortality compared to rosuvastatin (HR 1.29) 8
• This difference was not observed in patients with normal liver enzymes 8
• Meta-analysis of short-term adverse events showed no significant difference in ALT elevations >3x ULN between the two drugs 9

Muscle-Related Adverse Events

No significant differences in myalgia or CK elevations:

• Meta-analysis of 20,000 patients found no significant differences in myalgia, CK >10x ULN, or discontinuation rates 9
• Both drugs showed similar tolerability profiles across dose ranges 3

Special Population Considerations

Renal Impairment

Atorvastatin may be preferred in chronic kidney disease:

• Both statins improved glomerular filtration rate, but atorvastatin has been suggested as potentially advantageous in renal impairment based on pharmacokinetic properties 10
• No significant difference in end-stage kidney disease development was observed in real-world data 6

Heart Failure

Atorvastatin may have advantages in heart failure with concomitant CAD:

• Review suggests atorvastatin may be preferred in this population, though direct comparative trials are limited 10

Acute Myocardial Infarction with Liver Dysfunction

Rosuvastatin is preferred in AMI patients with elevated liver enzymes:

• Target trial emulation showed significantly lower mortality with rosuvastatin in this specific population 8

Dosing Equivalency

Approximate dose equivalents for similar LDL-C lowering:

• Rosuvastatin 5 mg ≈ Atorvastatin 10 mg 2, 3
• Rosuvastatin 10 mg ≈ Atorvastatin 20 mg 2, 3
• Rosuvastatin 20 mg ≈ Atorvastatin 40-80 mg 2, 3
• Rosuvastatin 40 mg ≈ Atorvastatin 80 mg (though rosuvastatin still shows slight superiority) 3

Drug Interactions

Ritonavir interactions differ significantly:

• Atorvastatin exposure increases 4.76-fold with ritonavir, requiring dose reduction to 25-50% of original dose during nirmatrelvir/ritonavir treatment 11
• Rosuvastatin shows minimal interaction with ritonavir (only 1.94-fold increase in Cmax, unchanged AUC), requiring no dose adjustment 11

Cost Considerations

Generic availability affects practical decision-making:

• Both drugs are now available as generics 10, 12
• Switching from brand-name atorvastatin to generic rosuvastatin resulted in 16% reduction in medical expenses with comparable outcomes 12

Clinical Decision Algorithm

Choose Rosuvastatin when:

• Maximum LDL-C lowering is the primary goal 2, 3
• Patient has elevated liver enzymes and acute coronary syndrome 8
• Patient requires concomitant nirmatrelvir/ritonavir therapy 11
• HDL-C elevation and triglyceride lowering are important secondary goals 3, 4

Choose Atorvastatin when:

• Patient has diabetes risk factors or established prediabetes (to minimize new-onset diabetes) 5
• Patient has chronic kidney disease or heart failure with CAD 10
• Patient has history of cataracts or cataract risk factors 5
• Cost is a primary consideration and local pricing favors atorvastatin 10

Either statin is appropriate when:

• Goal is moderate-intensity therapy (30-49% LDL-C reduction) 1
• Patient has no specific risk factors favoring one over the other 5, 12
• Primary prevention in intermediate-risk patients 7